126296-17-1

Upstream product

• 2472-13-1 6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-one 
• 100-46-9 benzylamine 

Downstream Products

• 153969-40-5 N-(2'-methylbenzoyl)-N-benzyl-6,7-dimethoxy-3,4-dihydro-2-naphthylamine 
• 153969-36-9 N-(3'-methylbenzoyl)-N-benzyl-6,7-dimethoxy-3,4-dihydro-2-naphthylamine 
• 126296-08-0 trans-6-benzyl-10,11-dimethoxy-5,6,6a,7,8,12b-hexahydrobenzophenanthridin-5-one 
• 153969-32-5 N-(4'-methylbenzoyl)-N-benzyl-6,7-dimethoxy-3,4-dihydro-2-naphthylamine 
• 167557-69-9 N-(4'-ethylbenzoyl)-N-benzyl-6,7-dimethoxy-3,4-dihydro-2-naphthylamine 

Relevant academic research and scientific papers

DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE

Described herein are small molecule agonists of dopamine receptor D1 that inhibit YAP/TAZ, compositions, and methods of using these compounds and compositions.

DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION

Trans-hexahydrobenzo[a]phenanthridines of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are disclosed. Pharmaceutical formulations including

Co-administration of dopamine-receptor binding compounds

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors

Dihydrexidine [4; (±)-trans- 10, 11-dihydroxy-5,6,6a,7,8,12b- hexahydrobenzo[a]phenanthridine (DHX)], the first high-affinity full D1 agonist, also is known to have significant D2 activity. The present work reports the synthesis and pharmacological activity of a series of analogs substituted in the pendent phenyl ring (i.e., 2-, 3-, or 4-position). (±)- trans-2-Methyl-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine (5) was a high-affinity D1 agonist, having approximately 4-fold greater D1 vs D2 selectivity than DHX itself. All of the analogs containing a methyl or ethyl (but not a phenyl) substituent at the 2-, 8-, or 4-position had a pharmacological profile similar to that of the lead compound DHX (4). Each analog was found to be a high-affinity full agonist with moderate selectivity for the D1 receptor. It is apparent from these results that the D1 receptor can tolerate small substituents at the 2-, 3-, and 4-positions of the pendent phenyl ring. On the basis of earlier studies showing that N-alkylation increases D2 selectivity, the 3-methyl N-n-propyl and 4-methyl N-n-propyl compounds 11 and 18 were synthesized. While these analogs exhibited much higher affinity for the D2 receptor, surprisingly 4-methyl-N-propyl-DHX (13) exhibited high affinity for both the D1 and D2 receptors. It was subsequently established that this compound is a selective D3 ligand (110- fold selectivity for the D3 over D2 receptor). The results from these studies demonstrate that several of the hexahydrobenzo[a]phenanthridine derivatives are agonists with high intrinsic activity that may serve as powerful tools to explore the structural features that determine affinity and selectivity (relative to the D2 receptor) of drugs for D1 receptors.

trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzophenanthridine: A Highly Potent Selective Dopamine D1 Full Agonist

trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzophenanthridine (4a, dihydrexidine) has been found to be a highly potent and selective agonist of the dopamine D1 receptor in rat brain.Dihydrexidine had an EC50 of approximately 7